L-DOPA and glia-conditioned medium have additive effects on tyrosine hydroxylase expression in human catecholamine-rich neuroblastoma NB69 cells

J Neurochem. 2001 Aug;78(3):535-45. doi: 10.1046/j.1471-4159.2001.00440.x.

Abstract

The aim of this study was to investigate the effect of L-DOPA and glia-conditioned medium (GCM) on cell viability, tyrosine hydroxylase (TH) expression, dopamine (DA) metabolism and glutathione (GSH) levels of NB69 cells. L-DOPA (200 microM) induced differentiation of NB69 cells of more than 4 weeks in vitro, as shown by phase-contrast microscopy and TH immunocytochemistry, and decreased replication, as shown by 5-bromodeoxyuridine immunostaining. L-DOPA did not increase the number of necrotic or apoptotic cells, as shown by morphological features, Trypan Blue, lactate dehydrogenase activity, bis-benzimide staining and TUNEL assay. Furthermore, L-DOPA (200 microM) increased Bcl-xL protein expression. Incubation of cells with L-DOPA (50, 100, 200 microM) for 24 h resulted in an increase in TH protein levels (174, 196 and 212% versus control). Neither carbidopa, an inhibitor of L-aromatic amino acid decarboxylase enzyme, nor L-buthionine sulfoximine, which inhibits GSH synthesis, or ascorbic acid, an antioxidant, blocked the L-DOPA-induced effect on TH protein expression. L-DOPA (0, 50, 100 and 200 microM) plus GCM further increased the amount of TH protein (346, 446, 472 and 424%). L-DOPA (200 microM) increased TH protein levels to 132, 191 and 245% of controls after incubation for 24, 48 and 72 h. DA metabolism in NB69 cells was increased in cultures treated with either L-DOPA (200-300 microM) or GCM and these two agents had a synergistic effect on DA metabolism. In addition, L-DOPA (200 microM) or/and GCM-treated cells increased their GSH extracellular levels (223, 257, 300% of controls) after 48 h of treatment. The L-DOPA-induced increase of TH protein expression in NB69 cells was independent of DA production, free radicals and GSH up-regulation.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antioxidants / pharmacology
  • Apoptosis / drug effects
  • Ascorbic Acid / pharmacology
  • Buthionine Sulfoximine / pharmacology
  • Carbidopa / pharmacology
  • Cell Differentiation / drug effects
  • Culture Media, Conditioned
  • Culture Media, Serum-Free
  • Dopamine / metabolism
  • Dopamine Agents / pharmacology
  • Dose-Response Relationship, Drug
  • Enzyme Inhibitors / pharmacology
  • Glutathione / metabolism
  • Humans
  • Immunoblotting
  • Immunohistochemistry
  • In Situ Nick-End Labeling
  • Levodopa / pharmacology*
  • Neuroblastoma
  • Neuroglia / metabolism*
  • Neurons / cytology
  • Neurons / enzymology*
  • Proto-Oncogene Proteins c-bcl-2 / metabolism
  • Time Factors
  • Tumor Cells, Cultured
  • Tyrosine 3-Monooxygenase / genetics
  • Tyrosine 3-Monooxygenase / metabolism*
  • bcl-X Protein

Substances

  • Antioxidants
  • BCL2L1 protein, human
  • Culture Media, Conditioned
  • Culture Media, Serum-Free
  • Dopamine Agents
  • Enzyme Inhibitors
  • Proto-Oncogene Proteins c-bcl-2
  • bcl-X Protein
  • Levodopa
  • Buthionine Sulfoximine
  • Tyrosine 3-Monooxygenase
  • Glutathione
  • Carbidopa
  • Ascorbic Acid
  • Dopamine